PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Fittingly enough, for its third acquisition in as many years, Deerfield Group has picked up Triple Threat Communications. | ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

A Qatar-based study involving 121,700 patients has underscored the importance of the post-vaccination monitoring to optimise ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

U.S.-headquartered Alloy Therapeutics, a biotech firm focused on expanding access to drug discovery tools, said it has signed a memorandum of understanding with Serbia's state-owned operator of the ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said it will pay up to $951 million to acquire LaNova Medicines, which has ...

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) ('Ascentage” or the 'Company”), a global ...

Antibiotic innovation, rising female UTI cases, and diagnostic advances are key drivers shaping the future of the UTI market. CA, UNITED STATES, July 15, 2025 /EINPresswire.com/ -- Urinary tract ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...